TABLE 2.

CHANGE IN CLINICAL CHARACTERISTICS AFTER ENDOTOXIN ADMINISTRATION

	Placebo (n = 6)	Lovastatin (n = 6)	rhAPC (n = 6)	P Value
Change in vital signs*
Temperature, °C	0.4 ± 0.4	0.7 ± 0.4	0.6 ± 0.3	0.51
Systolic blood pressure, mm Hg	−18 ± 5	−16 ± 16	−15 ± 4	0.88
Diastolic blood pressure, mm Hg	−13 ± 6	−11 ± 13	−10 ± 8	0.86
Mean arterial pressure, mm Hg	−14 ± 5	−13 ± 14	−12 ± 9	0.86
Heart rate, beats/min	30 ± 10	20 ± 6	30 ± 12	0.15
Respiratory rate, breaths/min	4 ± 4	2 ± 3	2 ± 3	0.58
Change in pulmonary function tests
FVC, L	−0.23 ± 0.29	−0.15 ± 0.36	−0.22 ± 0.40	0.93
FVC, % predicted	−4.8 ± 6.7	−4.3 ± 9.8	−5.3 ± 8.87	0.98
FEV1, L	−0.32 ± 0.29	−0.05 ± 0.36	−0.18 ± 0.29	0.37
FEV1, % predicted	−7.8 ± 6.9	−3.8 ± 11.0	−5.3 ± 9.2	0.75
SaO2,* %	−2 ± 1	−3 ± 2	−4 ± 3	0.42
Change in hematologic parameters
White blood cells, × 103/μl	1.5 ± 1.8	4.3 ± 2.4	3.0 ± 1.8	0.10
Neutrophils, %	5.3 ± 7.8	17.2 ± 6.9†	8.5 ± 8.0	0.04
Lymphocytes, %	−5.3 ± 3.2	−15.0 ± 2.2†	−7.3 ± 2.8	0.03
Monocytes, %	0.7 ± 1.4	−2.1 ± 0.7	−1.7 ± 0.6	0.12
Eosinophils, %	−0.4 ± 0.5	−0.2 ± 0.3	0.7 ± 0.3	0.13
Hematocrit, %	−0.8 ± 2.0	−1.4 ± 2.2	−2.4 ± 2.4	0.47
Platelets, × 103/μl	−30 ± 24	−26 ± 10	−49 ± 31	0.24
International normalized ratio	0.003 ± 0.06	0.02 ± 0.04	0.12 ± 0.05‡	0.002
Change in serum chemistry values
Creatinine, mg/dl	0.03 ± 0.1	−0.03 ± 0.08	−0.05 ± 0.05	0.21
Bilirubin, mg/dl	−0.07 ± 0.2	−0.11 ± 0.26	−0.07 ± 0.08	0.89
AST, IU/L	−5 ± 7	3 ± 16	−5 ± 2	0.36
ALT, IU/L	−5 ± 5	−3 ± 5	−6 ± 4	0.49
Glucose, mg/dl	2.4 ± 5.9	5.9 ± 6.4	2.7 ± 5.5	0.55

Values represent means ± SD for postendotoxin measurement minus preendotoxin measurement.

^*Represents maximal change from baseline.

^†Significant difference compared with placebo.

^‡Significant difference compared with both placebo and lovastatin cohorts.